Kelvin Teo, MBBS, PhD, senior consultant, Advanced Eye Clinic & Surgery, adjunct associate professor, Duke NUS Eye ACP, Singapore, presents real-world data showing that a single 8-mg dose…
Andrew Chang, MBBS, PhD, consultant ophthalmologist and head of Ophthalmology, Sydney Eye Hospital, Australia, shares real-world experience using 8-mg intravitreal aflibercept for neovascular age-related macular degeneration and reports…
A pilot study showing improved outcomes for metastatic renal cell carcinoma (mRCC) patients who were treated with immune checkpoint therapy after surgery, as compared with just immune checkpoint…
Recurrence after metastasectomy is common for patients with metastatic renal cell carcinoma (mRCC). In this study, treating with pazopanib after metastasectomy was shown to offer no additional survival…
The US Food and Drug Administration (FDA) has approved the immunotherapy avelumab in combination with the tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The…
